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Objectives. To assess the immunogenicity of intradermal (ID) booster doses of Puriﬁed Chick Embryo Cell rabies vaccine (PCECV,
Rabipur) administered to Thai schoolchildren one, three and ﬁve years after a primary ID pre-exposure (PrEP) vaccination series.
Methods. In this follow-up study of a randomized, open-label, phase II clinical trial, two simulated post-exposure booster doses
of PCECV were administered on days 0 and 3 intradermally to 703 healthy schoolchildren, one, three or ﬁve years after primary
vaccination with either two or three ID doses of 0.1mL PCECV. Blood was drawn immediately before and 7, 14 and 365 days after
the ﬁrst booster dose to determine rabies virus neutralizing antibody (RVNA) concentrations. Results. An anamnestic response
of approximately 30-fold increase in RVNA concentrations was demonstrated within 14 days after booster. All children (100%)
developed adequate RVNA concentrations above 0.5IU/mL. No vaccine related serious adverse events were seen in any of the
vaccinees. Conclusion. ID rabies PrEP with PCECV is safe and immunogenic in schoolchildren and the anamnestic response to a
two booster dose vaccination series was found to be adequate one, three, and ﬁve years after a two- or three-dose primary PrEP
vaccination series.
1.Introduction
Rabies post-exposure prophylaxis (PEP) after an exposure
to a rabid animal has been demonstrated to be eﬃcacious
using tissue culture vaccines (TCV) including puriﬁed chick
embryocellvaccine(PCECV),administeredeitherintramus-
cularly (IM) or intradermally (ID) [1, 2]. However, human
rabies remains a signiﬁcant health problem in countries of
Asia and Africa, where more than 99% of the exposures
come from rabies-infected dogs that inhabit rural and urban
areas. The vast majority of the estimated 55,000 human
deaths that occur worldwide every year occur on these two
continents [3, 4], mainly due to lack of awareness that results
in delayed, inadequate PEP, or even no PEP administered to
patients exposed to rabid animals. A signiﬁcant number of
bite exposures and rabies cases occur in children under 15
years of age [5–8]. It has been reported that in Thailand by
the age of 15 years approximately one-third of all children
will have experienced a dog bite, indicating the potential risk
for children to be exposed to a rabid animal [9]. While PEP
clearly saves lives, human rabies cases, especially in children,
continue to occur despite the availability of vaccines and
biologicals. Almost all of these human rabies cases could
have been prevented, and almost all occurred due to a lack
of receiving PEP. One possible alternative to making sure
that every child received adequate PEP after exposure is to
administer pre-exposure prophylaxis (PrEP) to those living
in high-risk regions. The use of PrEP in children living in2 Advances in Preventive Medicine
Table 1: Number and percentage of children reaching adequate RVNA concentrations (≥0.5IU/mL) after administration of simulated
post-exposure booster doses, 1, 3, or 5 years after two or three primary vaccination doses, as determined by RFFIT.
Group 1-year 3-year 5-year
pre D7 D14 D365 pre D7 D14 D365 Pre D7 D14 D365
2d (6/84) (81/84) (81/81) (51/77) (4/48) (35/48) (47/47) (24/41) (10/82) (75/82) (79/79) (29/57)
% 7% 96% 100% 66% 8% 73% 100% 59% 12% 91% 100% 51%
3d (22/63) (61/61) (58/58) (55/59) (24/60) (58/60) (57/57) (45/52) (41/89) (88/89) (85/85) (59/62)
% 35% 100% 100% 93% 40% 97% 100% 87% 46% 99% 100% 95%
2d: two-dose primary vaccination; 3d: three-dose primary vaccination; pre: before booster.
areas of high risk of exposure to rabies would reduce the
number of vaccine booster doses required and eliminate the
need to administer rabies immunoglobulin (RIG) after an
exposure has occurred. For example, persons that have been
vaccinated previously with a tissue culture rabies vaccine
and are subsequently exposed to a rabid animal only require
two booster doses of vaccine, administered on days 0 and 3,
either IM or ID [4]. Previous reports have demonstrated that
PCECV is immunogenic and safe when given intradermally
[10–12]. Recent studies from Thailand and India revealed
that the current WHO PrEP recommendations of three IM
or ID doses are adequate in schoolchildren [13, 14]a n d
toddlers[15].AstudyusingPCECVintoddlersadministered
concomitantly with Japanese encephalitis vaccine (JEV)
demonstrated adequate tolerability and immunogenicity of
both vaccines and indicated the suitability of introducing
rabies vaccine into the Expanded Program on Immunization
(EPI) schedule. In addition, a study with puriﬁed verocell
rabies vaccine (PVRV) was conducted in infants, indicating
adequateimmuneresponseswhenrabiesvaccinewasadmin-
istered concomitantly with pediatric routine combination
vaccine (diphtheria, tetanus, whole cell pertussis, inactivated
poliomyelitis; DTP-IPV) [16]. However, when infant or pre-
school rabies vaccinations are missed, vaccination in early
school-agechildrencouldbeapracticalandeﬃcientsolution
to protect this most vulnerable population against rabies. In
this study we investigated whether two or three ID doses of
PCECV would be immunogenic in children and concluded
that the current recommendation of three doses given ID is
appropriate [13]. The study population, clinical trial design,
and results of the primary vaccination have been published
earlier [13].
2. Methods
2.1. Clinical Trial. In this long-term followup, the anamnes-
tic response of Thai schoolchildren that received two
(simulated) post-exposure booster doses of PCECV was
investigated up to ﬁve years after the primary vaccination
PrEP series was administered. Details of the study conduct
have been described earlier [13]. Brieﬂy, subjects enrolled
in the clinical trial included healthy schoolchildren, aged 5
to 8 at the time that the primary vaccination with two or
three 0.1mL ID doses of PCECV was administered. Subjects
were followed for one, three, or ﬁve years after primary PrEP
and then received two ID booster doses of 0.1mL PCECV
on days 0 and 3, simulating the current recommended
PEP booster recommendations, that is, administering the
2-dose booster doses, without RIG, as if an exposure had
occurred. The PCECV used for the primary vaccination
series and for the 1-year and 3-year booster doses was
Novartis Vaccines’ Rabipur, produced in India; batch no.
725 (potency 7.25IU/mL). For the 5-year group, batch no.
1471 (potency 9.81IU/mL) was used. The objectives of the
study were to demonstrate long-term postbooster rabies
virus-neutralizing antibody (RVNA) protection, deﬁned as
RFFIT antibody concentrations ≥0.5IU/mL, one, three, and
ﬁve years after the primary vaccination, to evaluate whether
adequateRVNAconcentrationsisachievedinallsubjectsand
to compare the immune responses of the 2-dose versus 3-
dose ID regimen of PCECV. This study was conducted under
the auspices of the Ministry of Public Health, Thailand,
following the research principles set out in the Declaration
of Helsinki and Good Clinical Practice guidelines. Approval
of the study protocol was obtained by the Ethical Review
Committee for Research in Human Subjects, Ministry of
Health; all parents and legal guardians of subjects were
informed of the study protocol prior to enrollment, and
written informed consent was obtained from parents or legal
guardians of all subjects prior to enrollment. The study was
registered at ClinicalTrials.gov (identiﬁer: NCT01107275).
A ﬂow diagram of study participants as suggested in the
CONSORT Statement is given in Figure 1.
2.2. Serology. Blood was drawn before administration of the
ﬁrst of two booster doses and on days 7, 14, and 365 days
later. Serology testing was performed in the same laboratory
as in the ﬁrst part of the study, (Queen Saovabha Memorial
Institute, Bangkok, Thailand) for determination of RVNA
concentrations, using the rapid ﬂuorescent focus inhibition
test (RFFIT), as described earlier [17].
3. Results
One year after the primary vaccination, RVNA concentra-
tions had decreased (Figure 2(a)) with 7% and 35% of the
vaccinees still having adequate RVNA concentrations above
0.5IU/mL, in the 2-dose and 3-dose group, respectively,
(Table 1). This percentage of subjects with adequate RVNA
concentrations did not change signiﬁcantly over time (Fig-
ures 2(b) and 2(c)); 8% and 40% of subjects in the 3-year
group and 12% and 46% of subjects in the 5-year group,
respectively, maintained adequate RVNA concentrations
(Table 1). After receiving two booster doses of PCECV, onAdvances in Preventive Medicine 3
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Figure 1: Flow diagram of study participants (according to CONSORT Statement).
day0andday3,RVNAconcentrationsincreasedsigniﬁcantly
in all study groups, thus eliciting adequate RVNA concen-
trations on day 7 postbooster in 100%, 97%, and 99% of
the children in the 3-dose groups, and 96%, 73%, and 91%
of the children in the 2-dose group, at one, three, and ﬁve
years after primary vaccination, respectively. By day 14, every
child (100%) had reached adequate RVNA concentrations,
regardless of the time interval between primary vaccination
and booster or whether having received two or three primary
doses (Table 1). Thus the objective was met to demonstrate
long-term postbooster RVNA protection, deﬁned as RFFIT
antibody concentrations ≥0 . 5I U / m L ,1 ,3 ,a n d5y e a r sa f t e r
the primary vaccination, as well as to demonstrate that
adequate RVNA concentrations are achieved in all subjects.
Fourteen days after booster, the 2-dose regimen proved equi-
valent to the 3-dose regimen in eliciting adequate response
(100% adequate RVNA concentrations in all groups), while
on day 7 after booster, the percentage was lower in the 2-
dose group. When comparing actual RVNA concentrations,
GMCs were about 3-fold higher in the 3-dose group than in
the 2-dose group. This diﬀerence was seen throughout the
study (Figure 2).
4. Discussion
When a person has been previously immunized with a PrEP
seriesofthreedosesofrabiesvaccine,thecurrentrecommen-
dations for PEP include the administration of two booster
doses of a WHO-recommended tissue culture vaccine. It is
neither necessary nor recommended to administer RIG to
individuals that have received a tissue culture vaccine previ-
ously. The question as to whether the time interval between
primaryvaccinationseriesandthePEPboosterseriesfollow-
ing an exposure has an inﬂuence on the ability of a patient
to elicit an anamnestic response is an important concern for
publichealthoﬃcialsthatmaybeconsideringtheuseofPrEP
toprotectpopulationslivinginareaswithahighriskofexpo-
sure to rabies. In this study we investigated the anamnestic
response in subjects that had received a two booster dose
seriesofPEPone,three,andﬁveyearsaftertheprimaryPrEP
immunization, and we have conﬁrmed that an adequate and
rapid immune response occurred in all subjects.
Interestingly, RVNA concentrations and the percentage
of patients that produced adequate titers did not change
signiﬁcantly over the years. In subjects that had been4 Advances in Preventive Medicine
Days
0 90 180 270 360
G
M
C
(
I
U
/
m
L
)
0.1
1
10
100
0.5IU/mL
1-year
(a)
Days
0 90 180 270 360
G
M
C
(
I
U
/
m
L
)
0.1
1
10
100
0.5IU/mL
3-year
(b)
Days
0 90 180 270 360
G
M
C
(
I
U
/
m
L
)
0.1
1
10
100
0.5IU/mL
5-year
(c)
Figure 2: Immune response after two simulated post-exposure intradermal 0.1mL booster doses of PCECV on days 0 and 3, administered
one (a), three (b), or ﬁve years (c) after completion of a primary vaccination series. : 2 ID doses; : 3 ID doses; error bars represent 95%
conﬁdence intervals ···: RVNA concentrations regarded as adequate for protection. (0.5 IU/mL).
vaccinated ﬁve years previously, approximately the same
RVNA concentrations were observed as in subjects that had
been vaccinated one and three years earlier. After the two-
booster dose PEP series, a comparable immune response was
observed in all subjects regardless of the time elapsed since
theirinitialPrEPseries.Amorerelevantconsiderationishow
many doses were included in the initial primary vaccination
series: those subjects that received a three-dose primaryAdvances in Preventive Medicine 5
PrEP series had higher levels of RVNA concentrations and
higher booster responses than subjects that received only a
two-dose primary PrEP series (Figure 2). However, although
GMTs of RVNA concentrations in the group that received
a two-dose PrEP series were signiﬁcantly lower throughout
the study, in this group all subjects achieved adequate RVNA
concentrations above 0.5IU/mL, when two booster doses
were given up to ﬁve years after primary vaccination. The
fact that all subjects reached adequate RVNA concentrations
by day 14, regardless of the time interval between primary
series, and booster doses or the number of doses in
the primary series is reassuring. However, the overall lower
RVNAconcentrationsinthe2-dose groupresultedinalower
percentage of adequate RVNA concentrations on day 7. In
particular, in the 2-dose group adequate immune responses
were only seen in 73% of children (3-year data), compared
to 97–100% in the 3-dose groups. This leaves a vulnerable
period of a few days in more than few subjects after a
2-dose primary vaccination series. Whether this would lead
to treatment failure and development of rabies remains
questionable. In PEP of previously unvaccinated subjects,
adequate RVNA concentrations do not develop before day
14 either. Clearly here RIG is recommended to cover the
lag period. However, in reality RIG is only administered
in 2 to 10% of all cases, where it would be indicated [18],
and treatment failures are seen extremely rarely. To be
on the safe side, however, as administration of RIG is
not considered necessary or recommended for previously
vaccinated subjects, a 3-dose primary vaccination regimen
might be considered more suitable for individual protection.
Additionallythequestionhowtoprovepreviousvaccina-
tion has to be discussed. It is not uncommon that children
or parents forget about the vaccines that they had been
given. A serologic testing may not be a suitable method for
proofofearliervaccination.Suchtestingmaynotbeavailable
everywhere, is quite expensive, and—most critically—would
provide results too late for a decision whether to give booster
doses without RIG or whether to start a complete series of
PEP, including RIG when indicated. Therefore, a system of
documentation of each vaccination in a booklet is preferred.
As a matter of fact, in absence of documented proof of
vaccination, a full PEP course including administration of
RIG would be required.
TheWHOrecommendsthatdiagnosticlaboratorywork-
ers, rabies researchers, and other people at continuous
risk (where rabies virus is present continuously, often
in high concentrations, and where speciﬁc exposures to
rabies are likely to go unrecognized) should have their
serological titers evaluated every six months for the presence
of RVNA and receive a single booster vaccination when
their RVNA concentrations fall below 0.5IU/mL [4]. For
the general population living in endemic countries, it
is suﬃcient to receive a routine ID booster series with
0.1mL of PCECV without routine serology testing, which
is expensive and diﬃcult to perform. Due to the fact that
immune memory is established in persons that have been
vaccinated with a TCV, an anamnestic immune response
is induced after a PEP-booster series using 0.1mL of a
TCV (PCECV) ID booster doses, as demonstrated in this
study up to ﬁve years after completion of the primary
vaccination.
The results of this study are in line with results from
another study investigating abbreviated and less doses intra-
dermal pre-exposure vaccination schedules. In one of the
study arms, Khawplod and coworkers administered two ID
doses at two sites on a single visit as primary vaccination,
using PCECV or PVRV. Upon two ID booster doses (Day 0
and3)oneyearlater,allsubjectselicitedanamnesticimmune
responses and adequate RVNA concentrations [19].
A striking additional ﬁnding in our study was that 12 of
703 children (1.7%) were actually exposed to rabies by
potentially rabid animals during the study period. These
were given appropriate PEP as predeﬁned in the study
protocol, and they were further excluded from serology
analyses but were followed for a period of one year. All
remained healthy during the observation period. The high
number of exposures clearly shows that rabies is an endemic
threat to children in Thailand.
5. Conclusion
While the current recommendation of PrEP vaccination
consists of three doses of rabies vaccine administered ID or
IM [4], a PrEP vaccination series using two or three doses
of 0.1mL PCECV administered ID is safe and immunogenic
in school children, and anamnestic responses occurred in all
subjects after two booster doses were administered up to ﬁve
years later. This indicates that when an exposure occurs, two
booster doses of vaccine administered ID three days apart
may be appropriate in previously immunized persons that
may have received only two initial doses of a PrEP series
although three initial doses lead to higher immune responses
and longer lasting protection. Reduced PrEP regimens
would reduce the cost of protecting vulnerable populations
against rabies and would promote better compliance, thus
supporting opportunities to conduct mass PrEP rabies
vaccination in children, the population most at risk of dying
of this dreaded disease.
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